Cargando…

Formulated Phospholipids as Non-Canonical TLR4 Agonists

Immunogenic agents known as adjuvants play a critical role in many vaccine formulations. Adjuvants often signal through Toll-like receptor (TLR) pathways, including formulations in licensed vaccines that target TLR4. While TLR4 is predominantly known for responding to lipopolysaccharide (LPS), a com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hong, Lykins, William R., Seydoux, Emilie, Guderian, Jeffrey A., Phan, Tony, Fox, Christopher B., Orr, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788208/ https://www.ncbi.nlm.nih.gov/pubmed/36559051 http://dx.doi.org/10.3390/pharmaceutics14122557

Ejemplares similares

The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine
por: Liang, Hong, et al.
Publicado: (2019)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions
por: Fisher, Karl J., et al.
Publicado: (2023)

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
por: Fox, Christopher B, et al.
Publicado: (2014)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach
por: Fox, Christopher B., et al.
Publicado: (2016)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

Agonistic and Antagonistic Roles for TNIK and MINK in Non-Canonical and Canonical Wnt Signalling
por: Mikryukov, Alexander, et al.
Publicado: (2012)

Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
por: Jensen, Simon S, et al.
Publicado: (2013)

High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation
por: Gadd, Adam J.R., et al.
Publicado: (2018)

TLR Agonist Therapy of Metastatic Breast Cancer in Mice
por: Klinman, Dennis M., et al.
Publicado: (2023)

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
por: Fung, HW Millie, et al.
Publicado: (2013)

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
por: Lu, Ti, et al.
Publicado: (2023)

Screening of Oligomeric (Meth)acrylate Vaccine Adjuvants Synthesized via Catalytic Chain Transfer Polymerization
por: Hege, Cordula S., et al.
Publicado: (2023)

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine
por: Archer, Michelle C., et al.
Publicado: (2023)

A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection
por: Hedges, Jodi F., et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

Practical Considerations for Next-Generation Adjuvant Development and Translation
por: Lykins, William R., et al.
Publicado: (2023)

Canonical formulation of generalized coupled dispersionless system
por: Kakuhata, H, et al.
Publicado: (1997)

The Canonical Formulation Of Conservative Electromagnetic fields In cavities
por: Repalov, N S
Publicado: (1978)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages
por: Chu, Lan H., et al.
Publicado: (2018)

Nonbilayer Phospholipid Arrangements Are Toll-Like Receptor-2/6 and TLR-4 Agonists and Trigger Inflammation in a Mouse Model Resembling Human Lupus
por: Wong-Baeza, Carlos, et al.
Publicado: (2015)

Formulation, optimization, and pharmacodynamic evaluation of chitosan/phospholipid/β-cyclodextrin microspheres
por: Shan, Lu, et al.
Publicado: (2016)

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy
por: Abhyankar, Mayuresh M., et al.
Publicado: (2021)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Development of polyherbal antidiabetic formulation encapsulated in the phospholipids vesicle system
por: Gauttam, Vinod Kumar, et al.
Publicado: (2013)

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation
por: Auderset, Floriane, et al.
Publicado: (2019)

Surrogate Wnt agonists that phenocopy canonical Wnt/β-catenin signaling
por: Janda, Claudia Y., et al.
Publicado: (2017)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
por: Mirza, Sabiruddin, et al.
Publicado: (2010)

Immunometabolism Modulation by Extracts from Pistachio Stalks Formulated in Phospholipid Vesicles
por: Pani, Simone, et al.
Publicado: (2023)

Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood
por: Adeagbo, Babatunde Ayodeji, et al.
Publicado: (2020)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0mnjt7iotfq9ker9ca0dnlq3lq